In peritoneal dialysis (PD) patients, peritonitis is a serious
|
|
- Gregory Long
- 5 years ago
- Views:
Transcription
1 Proceedings of the ISPD 2006 The 11th Congress of the ISPD /07 $ August 25 29, 2006, Hong Kong Copyright 2007 International Society for Peritoneal Dialysis Peritoneal Dialysis International, Vol. 27 (2007), Supplement 2 Printed in Canada. All rights reserved. THE ACHILLES HEEL OF PERITONEAL DIALYSIS? Cheuk-Chun Szeto and Kai-Ming Chow Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, PR China Peritonitis caused by gram-negative bacteria is a serious complication of peritoneal dialysis. Antibiotic resistance is common, and response to medical treatment is often poor. In the present article, we review recent advances in the understanding of the pathogenesis and treatment of this serious condition. Perit Dial Int 2007; 27(S2):S267 S271 KEY WORDS: Renal failure; antibiotic resistance; extended-spectrum β-lactamase. In peritoneal dialysis (PD) patients, peritonitis is a serious complication (1 3) and probably the most important cause of technique failure (2 5). Although gram-positive organisms are the most common bacteriologic cause of PD-related peritonitis (1,6), the incidence of gram-positive infections is falling because of the advances in PD connectology (5,7,8). Gram-negative peritonitis may result from touch contamination, exitsite infection, or possibly a bowel source such as constipation, colitis, or transmural migration, but the cause is often unclear (9 12). Gram-negative organisms now account for 20% 30% of all PD-related peritonitis (5,13). CLINICAL OUTCOMES The clinical outcomes of gram-positive and gramnegative peritonitis are markedly different. In fact, when peritonitis rates are used to predict outcome, the suggestion has been made that the two groups of organisms should be examined separately (12). For example, in a retrospective study, Troidle et al. (11) reviewed 415 episodes of peritonitis that occurred in 375 PD patients between 1993 and As compared with Correspondence to: C.C. Szeto, Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, PR China. ccszeto@cuhk.edu.hk episodes of gram-positive peritonitis, episodes caused by gram-negative organisms were more likely to require hospital admission (74% versus 24%, p < 0.001) or catheter removal (18% versus 4%, p < 0.001) and to lead to relapse (32% versus 9%, p < 0.05). In the Network 9 Peritonitis Study (10), the risks of catheter loss, hospitalization, and technique failure in 136 episodes of non-pseudomonas gram-negative peritonitis were significantly worse than in 530 peritonitis episodes caused by gram-positive organisms. More recently, Choi et al. (14) reviewed 490 episodes of peritonitis that occurred between 1995 and In that series, 32% of gram-negative and 10% of gram-positive peritonitis episodes required catheter removal (p < ). In a previous series by our group, gram-negative peritonitis accounted for 43% of the episodes that required catheter removal (4). Although PD could be resumed after catheter re-insertion in about half of the cases, loss of solute clearance or ultrafiltration was common following an episode of severe peritonitis (4). SPECIFIC ORGANISMS P. aeruginosa, Escherichia coli, and Klebsiella species are the bacteria that most commonly cause gram-negative peritonitis, identified in 7.1%, 6.8%, and 5.2% of culture-positive cases respectively (15). Amongst all gram-negative organisms, Pseudomonas species are probably the most important cause of serious peritonitis in PD patients. We previously reported on 104 episodes of Pseudomonas peritonitis (16), which accounted for 13% of all peritonitis in our dialysis unit from 1995 to The major risk factors were a history of antibiotic therapy within 30 days before onset (66% of cases) and concomitant exit-site infection (45% cases). The overall primary response rate was 61%; the rate of complete cure was 22%. Presence of exit-site infection was associated with a lower primary response rate (47% vs 72%, p < 0.01) and S267
2 PROCEEDINGS OF THE 11TH CONGRESS OF THE ISPD JUNE 2007 VOL. 27, SUPPL 2 PDI a lower rate of complete cure (11% vs 32%, p < 0.02). The episodes that followed recent antibiotic therapy had a significantly lower rate of complete cure than did the de novo cases (12% vs 43%, p < 0.001). More importantly, among the 24 cases that required catheter removal, the chance of returning to PD was higher when the catheter was removed before day 10 than when it was removed on day 15 (64% vs 50%), although that result was not statistically significant. These findings suggest that, when response to antibiotic therapy is suboptimal, early removal of the catheter is important. Among all gram-negative organisms, those from the family Enterobacteriaceae, a large heterogeneous group of gram-negative bacteria, are most commonly involved in PD-related peritonitis. We recently reviewed 210 episodes of Enterobacteriaceae peritonitis, which constituted 12% of all peritonitis in our dialysis unit from 1995 to 2004 (17). The most common species was E. coli, which accounted for 111 episodes (53%). The overall primary response rate was 85%; the complete cure rate was 58%. Presence of exit-site infection was associated with a lower rate of complete cure (43% vs 61%, p = 0.034), but not primary response (89% vs 84%, p = 0.3). The episodes that followed recent antibiotic therapy had a marginally lower rate of complete cure than the others did (49% vs 63%, p = 0.06), but the response rate for primary infections was similar. A total of 82 episodes (39%) did not respond to treatment with a single antibiotic despite sensitivity in vitro, and a second antibiotic had to be added. Interestingly, patients treated with two antibiotics had a marginally lower risk of relapse and recurrence than did those treated with one antibiotic (21% vs 36%, p = 0.051). EVOLUTION IN EPIDEMIOLOGY Since the late 1980s, a substantial change has occurred in the pattern of causative organisms of PDrelated peritonitis. Zelenitsky et al. (15) reviewed 546 episodes of peritonitis that occurred in 374 patients during The rate of gram-positive peritonitis declined significantly to 0.28 episodes from 0.75 episodes per patient year during that period (p = 0.02), but the occurrence of gram-negative peritonitis remained constant at approximately 0.16 episodes per patient year. We recently reviewed 1787 episodes of PD-related peritonitis in 544 patients treated at our center during (5). From 1994 to 1998, the incidence of peritonitis caused by coagulase-negative staphylococci species declined to 0.06 episodes from 0.21 episodes per year on PD, paralleling a reduction in the use of the spike S268 set for PD during that period. In contrast, the incidence of E. coli and Klebsiella peritonitis remained static during the same period (Figure 1). Some evidence suggests that the severity of gramnegative peritonitis is worsening. For example, Valdes Sotomayor et al. (12) studied 49 episodes of E. coli peritonitis that occurred in two university hospitals during The duration of peritoneal inflammation was 3.1 ± 1.7 days for the episodes occurring before 1996, but 5.2 ± 2.7 days for those occurring after 1996 (p = 0.002). Catheter removal was needed in 19% of episodes before 1996 and in 39% episodes from 1996 onward (p = 0.012). It is distinctly possible that the increasing severity of peritonitis is at least partly related to increasing resistance to commonly used antibiotics. ANTIBIOTIC RESISTANCE Gram-negative bacteria have adapted to many antibiotics, especially the β-lactams, by modifying the substrate spectrum of common plasmid-mediated and chromosomal β-lactamases. With the liberal use of antibiotics in many countries, the incidence of resistance to common antibiotics is increasing. At our center, the response rate of gram-negative peritonitis to antibiotic therapy remained static for 10 years (5), but the percentage of cases that needed an alteration of the antibiotic regimen rose from 13.6% in 1994 to 58.7% in 2003 (Figure 2), indicating increasing prevalence of clinical antibiotic resistance. In the series by Zelenitsky et al. (15), the incidence of resistance to ciprofloxacin increased to 47.8% in 1998 from 5.4% in 1992 (p = 0.003). Our recent data on Enterobacteriaceae peritonitis also show that a gradual increase occurred in the prevalence of resistance to several commonly used antibiotics (17). Figure 1 Change in the incidence of gram-negative infections over 10 years.
3 PDI JUNE 2007 VOL. 27, SUPPL 2 PROCEEDINGS OF THE 11TH CONGRESS OF THE ISPD Figure 2 Change in the response rate to antibiotic treatment and percentage of cases that required an alteration of antibiotic regimen over 10 years. From 2001 to 2004, we observed a gradual increase in the prevalence of resistance to cephalothin and cefuroxime, but not to ceftazidime. A slight increase also occurred in prevalence of resistance to netilmicin or gentamicin, but the prevalence of resistance to ciprofloxacin remained constant. Recent antibiotic therapy was associated with resistance to cefotaxime, ceftazidime, cefoperazone/sulbactam, and piperacillin/tazobactam, accounting for 57%, 75%, 67%, and 80% of the resistant isolates respectively. It should be noted that an in vitro sensitivity test is often not a reliable guide for clinical practice, especially in the presence of bacterial biofilm adherent to a foreign body. Sepandj et al. (18) compared the minimum inhibitory concentration (MIC) and minimum biofilmeliminating concentration (MBEC) of 8 isolates of E. coli and another 8 isolates of Pseudomonas species. Antibiotic sensitivities were found to be significantly higher for the planktonic organisms as tested by MIC assay than for the same organisms in their biofilm state as tested by MBEC assay. For example, none of the isolates was resistant to ciprofloxacin by MIC assay, but 10 were resistant by MBEC assay. This observation indicates that clinical judgment concerning therapeutic response is important, and the presence of exit-site infection, which is a surrogate marker of biofilm formation, is a strong indicator of a need for more aggressive therapy. Extended-spectrum β-lactamase (ESBL) producing bacteria have been attracting special concern in recent years (19). In general, ESBL confers resistance to ceftazidime, cefotaxime, ceftriaxone, aztreonam, and other oxyimino-β-lactams and is found most often in Klebsiella species and E. coli, although it has also been detected in many other gram-negative pathogens. The prevalence of ESBL is probably underestimated because detection in clinical laboratories is imperfect (19). Traditionally, carbapenems are the ideal agents for therapy (19). Yip et al. (20) identified 11 episodes of ESBL-producing E. coli peritonitis over a period of 10 years. In their series, use of cephalosporins and gastric acid inhibitors were risk factors for ESBL-producing E. coli peritonitis. Compared with patients having non-esbl-producing E. coli peritonitis, patients with the ESBL-producing variant more often developed treatment failure (46% vs 13%, p = 0.02) and more often died of sepsis (27% vs 4%, p = 0.02). The peritoneal failure rate was also higher in the group infected with ESBL-producing organisms, although the difference was not statistically significant (18% vs 4%, p = 0.12). In our center, 7 of 103 isolates of E. coli and Klebsiella species from 1999 to 2003 were positive for ESBL (17). Of those 7 cases, 4 had recently received antibiotic therapy; 3 cases attained complete cure. Although carbapenems are the surest agents for therapy, the variety of β-lactamases that confer resistance to carbapenems is increasing, and overuse of any single class of antibiotic is likely to be followed by selection of pathogens resistant to that agent (19). STRATEGIES FOR PREVENTION As discussed earlier, the presence of exit-site infection, which is a surrogate marker of biofilm formation, is a strong indicator of need for more aggressive therapy. Exit-site mupirocin is effective in preventing Staphylococcus aureus exit-site infection. However, it does not reduce gram-negative infections. Bernardini et al. (21) recently reported a multicenter double-blind randomized controlled trial that compared daily gentamicin or mupirocin cream to the catheter exit site. Gentamicin cream applied daily to the catheter exit site reduced P. aeruginosa and other gram-negative catheter infections by more than 50%, and reduced peritonitis by 35%, particularly gram-negative peritonitis. In addition, gentamicin cream was as effective as mupirocin in preventing S. aureus infections. Moreover, gentamicin cream is notably less costly than is mupirocin, to which the incidence of resistance is rising. This study is particularly relevant to countries where gram-negative peritonitis is common. Once gram-negative peritonitis develops, suboptimal response to antibiotic therapy should lead to consideration of early catheter removal. Although the contemporary guideline recommends that catheter removal be considered by day 4, our recent data suggest that a dialysate cell count exceeding 1000/mm 3 on day 3 is a strong predictor of treatment failure and that early catheter removal should then be planned (22). S269
4 PROCEEDINGS OF THE 11TH CONGRESS OF THE ISPD JUNE 2007 VOL. 27, SUPPL 2 PDI Relapsed peritonitis is often caused by the persistence of bacterial biofilm on the catheter. Catheter exchange for patients with exit-site infection concurrent with peritonitis is a logical and effective measure to prevent relapse. Lui et al. (23) reviewed 37 patients with refractory Pseudomonas exit-site infection treated with catheter exchange in 1994 and In all patients, effective antibiotics were continued for 7 days, and PD was resumed 2 weeks after the surgery. None of the patients had recurrent exit-site infection at 4 weeks, and no case of Pseudomonas peritonitis occurred within 1 year. Similarly, in 14 episodes of Pseudomonas peritonitis with concomitant exit-site infection, we performed a catheter exchange procedure after the dialysis effluent cleared (16). In no case did relapse peritonitis occur within 1 year after the catheter exchange. These studies make a strong case for early elective catheter exchange in patients with persistent gram-negative exit-site infection. CONCLUSIONS Gram-negative peritonitis is a common cause of morbidity and treatment failure in PD patients. The incidence of peritonitis caused by gram-negative organisms has not decreased despite advances in connectology. In fact, evidence suggests that cases are becoming more severe, which is likely a result of an increasing prevalence of antibiotic resistance. Biofilm formation around the dialysis catheter is probably the major cause of relapse. In selected cases, early catheter removal and elective catheter exchange are effective strategies for preserving the peritoneum and preventing relapse. Further studies should focus on exit-site care, optimal antibiotic regimens, and measures to prevent or eradiate biofilm formation. ACKNOWLEDGMENTS This study was supported in part by the CUHK research accounts and REFERENCES S Piraino B. Peritonitis as a complication of peritoneal dialysis. J Am Soc Nephrol 1998; 9: Oreopoulos DG, Tzamaloukas AH. Peritoneal dialysis in the next millennium. Adv Ren Replace Ther 2000; 7: Szeto CC, Wong TY, Leung CB, Wang AY, Law MC, Lui SF, et al. Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney Int 2000; 58: Szeto CC, Chow KM, Wong TY, Leung CB, Wang AY, Lui SF, et al. Feasibility of resuming peritoneal dialysis after severe peritonitis and Tenckhoff catheter removal. J Am Soc Nephrol 2002; 13: Szeto CC, Leung CB, Chow KM, Kwan BC, Law MC, Wang AY, et al. Change in bacterial aetiology of peritoneal-dialysis-related peritonitis over ten years: experience from a center in South-East Asia. Clin Microbiol Infect 2005; 10: Prowant B, Nolph KD, Ryan L, Twardowski Z, Khanna R. Peritonitis in continuous ambulatory peritoneal dialysis: analysis of an 8-year experience. Nephron 1986; 43: Burkart JM, Hylander B, Durnell Figel T, Roberts D. Comparison of peritonitis rates during long-term use of standard spike versus Ultraset in continuous ambulatory peritoneal dialysis. Perit Dial Int 1990; 10: Li PK, Szeto CC, Law MC, Chau KF, Fung KS, Leung CB, et al. Comparison of double-bag and Y-set disconnect systems in continuous ambulatory peritoneal dialysis a randomized prospective multi-center study. Am J Kidney Dis 1999; 33: Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, et al. Peritoneal dialysis related infections recommendations: 2005 update. Perit Dial Int 2005; 25: Bunke CM, Brier M, Golper TA. Outcomes of single organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 Peritonitis Study. Kidney Int 1997; 52: Troidle L, Gorban Brennan N, Liger A, Finkelstein F. Differing outcomes of gram-positive and gram-negative peritonitis. Am J Kidney Dis 1998; 32: Valdes Sotomayor J, Cirugeda A, Bajo MA, del Peso G, Escudero E, Sanchez Tomero JA, et al. Increased severity of Escherichia coli peritonitis in peritoneal dialysis patients independent of changes in in vitro antimicrobial susceptibility testing. Perit Dial Int 2003; 23: Szeto CC, Li PK. Peritoneal dialysis-related infections. In: Pereira BJ, Sayegh MH, Blake P, eds. Chronic kidney disease, dialysis, and transplantation a companion to Brenner & Rector s the kidney. 2nd ed. Philadelphia: Saunders; Choi P, Nemati E, Banerjee A, Preston E, Levy J, Brown E. Peritoneal dialysis catheter removal for acute peritonitis: a retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization. Am J Kidney Dis 2004; 43: Zelenitsky S, Barns L, Findlay I, Alfa M, Ariano R, Fine A, et al. Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to Am J Kidney Dis 2000; 36: Szeto CC, Chow KM, Leung CB, Wong TY, Wu AK, Wang AY, et al. Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: a review of 104 cases. Kidney Int 2001; 59: Szeto CC, Chow VC, Chow KM, Lai RW, Chung KY, Leung CB, et al. Enterobacteriaceae peritonitis complicating peritoneal dialysis: a review of 210 consecutive cases. Kidney Int 2006; 69:
5 PDI JUNE 2007 VOL. 27, SUPPL 2 PROCEEDINGS OF THE 11TH CONGRESS OF THE ISPD 18. Sepandj F, Ceri H, Gibb A, Read R, Olson M. Minimum inhibitory concentration (MIC) versus minimum biofilm eliminating concentration (MBEC) in evaluation of antibiotic sensitivity of gram-negative bacilli causing peritonitis. Perit Dial Int 2004; 24: Jacoby GA, Munoz Price LS. The new β-lactamases. N Engl J Med 2005; 352: Yip T, Tse KC, Lam MF, Tang S, Li FK, Choy BY, et al. Risk factors and outcomes of extended-spectrum β-lactamase producing E. coli peritonitis in CAPD patients. Perit Dial Int 2006; 26: Bernardini J, Bender F, Florio T, Sloand J, PalmMontalbano L, Fried L, et al. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol 2005; 16: Chow KM, Szeto CC, Cheung KK, Leung CB, Wong SS, Law MC, et al. Predictive value of dialysate cell counts in peritonitis complicating peritoneal dialysis. Clin J Am Soc Nephrol 2006; 1: Lui SL, Yip T, Tse KC, Lam MF, Lai KN, Lo WK. Treatment of refractory Pseudomonas aeruginosa exit-site infection by simultaneous removal and reinsertion of peritoneal dialysis catheter. Perit Dial Int 2005; 25: S271
Enterobacteriaceae peritonitis complicating peritoneal dialysis: A review of 210 consecutive cases
http://www.kidney-international.org & 26 International Society of Nephrology original article see commentary on page 117 Enterobacteriaceae peritonitis complicating peritoneal dialysis: A review of 21
More informationPeritonitis is a serious complication of peritoneal dialysis
Coagulase Negative Staphylococcal Peritonitis in Peritoneal Dialysis Patients: Review of 232 Consecutive Cases Cheuk-Chun Szeto, Bonnie Ching-Ha Kwan, Kai-Ming Chow, Miu-Fong Lau Man-Ching Law, Kwok-Yi
More informationComparison of Gentamicin and Mupirocin in the Prevention of Exit-Site Infection and Peritonitis in Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 25, 2009 Anshinee Mahaldar, Michael Weisz, Pranay Kathuria Comparison of Gentamicin and Mupirocin in the Prevention of Exit-Site Infection and Peritonitis in Peritoneal
More informationRandomized, Double-Blind Trial of Antibiotic Exit Site Cream for Prevention of Exit Site Infection in Peritoneal Dialysis Patients
Randomized, Double-Blind Trial of Antibiotic Exit Site Cream for Prevention of Exit Site Infection in Peritoneal Dialysis Patients Judith Bernardini,* Filitsa Bender, Tracey Florio,* James Sloand, Linda
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. 8. Prophylactic antibiotics for insertion of peritoneal dialysis catheter
8. Prophylactic antibiotics for insertion of peritoneal dialysis catheter Date written: February 2003 Final submission: May 2004 Guidelines (Include recommendations based on level I or II evidence) Antibiotic
More informationPeritonitis is a serious complication of peritoneal dialysis
Staphylococcus aureus Peritonitis Complicates Peritoneal Dialysis: Review of 245 Consecutive Cases Cheuk-Chun Szeto, Kai-Ming Chow, Bonnie Ching-Ha Kwan, Man-Ching Law, Kwok-Yi Chung, Samuel Yu, Chi-Bon
More informationPeritoneal dialysis (PD) possesses advantages, such
Peritoneal Dialysis International, Vol. 34, pp. 308 316 doi: 10.3747/pdi.2013.00012 0896-8608/14 $3.00 +.00 Copyright 2014 International Society for Peritoneal Dialysis ESCHERICHIA COLI PERITONITIS IN
More informationRandomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis
Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis Steve SM Wong Alice Ho Miu Ling Nethersole Hospital Background PD peritonitis is a major cause of PD
More informationClinical course of peritonitis due to Pseudomonas species comtor. complicating peritoneal dialysis: A review of 104 cases
Kidney International, Vol. 59 (2001), pp. 2309 2315 Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: A review of 104 cases CHEUK-CHUN SZETO, KAI-MING CHOW, CHI-BON
More informationPeritoneal dialysis (PD) has been an established treatment
Peritoneal Dialysis International, Vol. 34, pp. 188 194 doi: 10.3747/pdi.2012.00233 0896-8608/14 $3.00 +.00 Copyright 2014 International Society for Peritoneal Dialysis MICROBIOLOGY AND OUTCOMES OF PERITONITIS
More informationDiagnosis: Presenting signs and Symptoms include:
PERITONITIS TREATMENT PROTOCOL CARI - Caring for Australasians with Renal Impairment - CARI Guidelines complete list ISPD Guidelines: http://www.ispd.org/lang-en/treatmentguidelines/guidelines Objective
More informationISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment
April 6, 2017 Mauro Verrelli, MD ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment, Li PK, Szeto CC, Piraino, B et al. Peritoneal Dialysis International, Vol. 36, pp. 481 508 Outline
More informationTREATMENT OF PERITONEAL DIALYSIS (PD) RELATED PERITONITIS. General Principles
WA HOME DIALYSIS PROGRAM (WAHDIP) GUIDELINES General Principles 1. PD related peritonitis is an EMERGENCY early empiric treatment followed by close review is essential 2. When culture results and sensitivities
More informationThe impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital
NDT Advance Access published July 26, 25 Nephrol Dial Transplant (25) 1 of 5 doi:1.193/ndt/gfi1 Original Article The impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. 10. Treatment of peritoneal dialysis associated fungal peritonitis
10. Treatment of peritoneal dialysis associated fungal peritonitis Date written: February 2003 Final submission: July 2004 Guidelines (Include recommendations based on level I or II evidence) The use of
More informationIntraperitoneal and Subsequent. Intravenous Vancomycin: An Effective Treatment Option for Gram-Positive Peritonitis in Peritoneal Dialysis
Open Access Journal of Clinical Nephrology Research Article Intraperitoneal and Subsequent ISSN 2576-9529 Intravenous Vancomycin: An Effective Treatment Option for Gram-Positive Peritonitis in Peritoneal
More informationProphylactic antibiotics for insertion of peritoneal dialysis catheter
Prophylactic antibiotics for insertion of peritoneal dialysis catheter Date written: October 2010 Final submission: September 2012 Author: Maha Yehia GUIDELINES a. Intravenous antibiotic prophylaxis should
More informationEmpiric antimicrobial use in the treatment of dialysis related infections in RIPAS Hospital
Original Article Brunei Int Med J. 2013; 9 (6): 372-377 Empiric antimicrobial use in the treatment of dialysis related infections in RIPAS Hospital Lah Kheng CHUA, Department of Pharmacy, RIPAS Hospital,
More informationThe new ISPD peritonitis guideline
Szeto Renal Replacement Therapy (2018) 4:7 DOI 10.1186/s41100-018-0150-2 REVIEW The new ISPD peritonitis guideline Cheuk Chun Szeto Open Access Abstract: Peritoneal dialysis (PD)-related infection encompasses
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationPeritonitis is a serious complication of peritoneal dialysis
Peritoneal Dialysis International, Vol. 30, pp. 311 319 doi: 10.3747/pdi.2008.00258 0896-8608/10 $3.00 +.00 Copyright 2010 International Society for Peritoneal Dialysis STAPHYLOCOCCUS AUREUS PERITONITIS
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationTreatment of peritonitis in patients receiving peritoneal dialysis Antibiotic Guidelines. Contents
Treatment of peritonitis in patients receiving Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Jude Allen (Pharmacist) Additional author(s): Dr David Lewis, Dr Dimitrios Poulikakos,
More information13. Treatment of peritoneal dialysis-associated peritonitis in adults
13. Treatment of peritoneal dialysis-associated peritonitis in adults Date written: February 2003 Final submission: July 2004 Guidelines (Include recommendations based on level I or II evidence) In peritoneal
More informationA Randomized, Double-Blinded Study for the Prevention of Exit Site Infections in Pediatric Peritoneal Dialysis Patients
A Randomized, Double-Blinded Study for the Prevention of Exit Site Infections in Pediatric Peritoneal Dialysis Patients Joshua Zaritsky, MD PhD, Barbara Gales, RN, Georgina Ramos, and Isidro B. Salusky,
More informationTo guide safe and appropriate selection of antibiotic therapy for Peritoneal Dialysis patients.
Nephrology Directorate Subject: Objective: Prepared by: Aintree Antibiotic Guidelines for Peritoneal Dialysis (PD): Catheter Insertion, and the Diagnosis and Treatment of PD Peritonitis and Exit-Site Infections.
More informationSt George/Sutherland Hospitals And Health Services (SGSHHS)
PERITONEAL DIALYSIS (PD) PERITONITIS MANAGEMENT AND TREATMENT Cross References (including NSW Health/ SESLHD policy directives) Medication Handling in NSW Public Health Facilities; NSW Health PD2013_043
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More informationAerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune
Original article Aerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune Patil P, Joshi S, Bharadwaj R. Department of Microbiology, B.J. Medical College, Pune, India. Corresponding
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationESBL Positive E. coli and K. pneumoneae are Emerging as Major Pathogens for Urinary Tract Infection
ESBL Positive E. coli and K. pneumoneae are Emerging as Major Pathogens for Urinary Tract Infection Muhammad Abdur Rahim*, Palash Mitra*. Tabassum Samad*. Tufayel Ahmed Chowdhury*. Mehruba Alam Ananna*.
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationSuccessful stewardship in hospital settings
Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com
More informationOriginal Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**
Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,
More informationAPPENDIX III - DOUBLE DISK TEST FOR ESBL
Policy # MI\ANTI\04\03\v03 Page 1 of 5 Section: Antimicrobial Susceptibility Testing Manual Subject Title: Appendix III - Double Disk Test for ESBL Issued by: LABORATORY MANAGER Original Date: January
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationRecurrent or severe exit-site infections (ESIs) and peritonitis
Peritoneal Dialysis International, Vol. 29, pp. 303 309 Printed in Canada. All rights reserved. 0896-8608/09 $3.00 +.00 Copyright 2009 International Society for Peritoneal Dialysis THE HONEYPOT STUDY PROTOCOL:
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationSummary of unmet need guidance and statistical challenges
Summary of unmet need guidance and statistical challenges Daniel B. Rubin, PhD Statistical Reviewer Division of Biometrics IV Office of Biostatistics, CDER, FDA 1 Disclaimer This presentation reflects
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationSamantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center
Samantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in
More informationInfection Control of Emerging Diseases
2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event
More informationTreatment for peritoneal dialysis-associated peritonitis (Review)
(Review) Wiggins KJ, Craig JC, Johnson DW, Strippoli GFM This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2008, Issue
More informationApril 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID
VOLUME FOUR; ISSUE 4 April 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID InPHARMation Pharmacy and Therapeutics Committee Update April 25 th, 2018 Meeting The Pharmacy and Therapeutics Committee
More informationPrevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia
Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia Ruta Paberza 1, Solvita Selderiņa 1, Sandra Leja 1, Jelena Storoženko 1, Lilija Lužbinska 1, Aija Žileviča 2*
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More information2. Peritoneal dialysis-associated peritonitis in children
2. Peritoneal dialysis-associated peritonitis in children Date written: February 2003 Final submission: July 2004 Guidelines No recommendations possible based on Level I or II evidence Suggestions for
More informationTaiwan Crit. Care Med.2009;10: %
2008 30% 2008 2008 2004 813 386 07-346-8339 E-mail srwann@vghks.gov.tw 66 30% 2008 1 2008 2008 Intensive Care Med (2008)34:17-60 67 2 3 C activated protein C 4 5,6 65% JAMA 1995;273(2):117-23 Circulation,
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationMili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh
Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationChanging trends in clinical characteristics and antibiotic susceptibility of Klebsiella pneumoniae bacteremia
ORIGINAL ARTICLE Korean J Intern Med 2018;33:595-603 Changing trends in clinical characteristics and antibiotic susceptibility of Klebsiella pneumoniae Miri Hyun, Chang In Noh, Seong Yeol Ryu, and Hyun
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationCentral Nervous System Infections
Central Nervous System Infections Meningitis Treatment Bacterial meningitis is a MEDICAL EMERGENCY. ANTIBIOTICS SHOULD BE STARTED AS SOON AS THE POSSIBILITY OF BACTERIAL MENINGITIS BECOMES EVIDENT, IDEALLY
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationReceived: February 29, 2008 Revised: July 22, 2008 Accepted: August 4, 2008
J Microbiol Immunol Infect. 29;42:317-323 In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationORIGINAL ARTICLE. Joanna Kabat Koperska, Edyta Gołembiewska, Kazimierz Ciechanowski
ORIGINAL ARTICLE Peritoneal dialysis related peritonitis in the years 2005 2007 among patients of the Peritoneal Dialysis Clinic of the Department of Nephrology, Transplantology and Internal Medicine,
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationDefining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationA retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya
A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,
More informationSafety of an Out-Patient Intravenous Antibiotics Programme
Safety of an Out-Patient Intravenous Antibiotics Programme Chan VL, Tang ESK, Leung WS, Wong L, Cheung PS, Chu CM Department of Medicine & Geriatrics United Christian Hospital Outpatient Parental Antimicrobial
More informationAntibiotic treatment in the ICU 1. ICU Fellowship Training Radboudumc
Antibiotic treatment in the ICU 1 ICU Fellowship Training Radboudumc Main issues Delayed identification of microorganisms Impact of critical illness on Pk/Pd High prevalence of antibiotic resistant strains
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationISPD GUIDELINES/RECOMMENDATIONS PERITONEAL DIALYSIS-RELATED INFECTIONS RECOMMENDATIONS: 2005 UPDATE
Peritoneal Dialysis International, Vol. 25, pp. 107 131 Printed in Canada. All rights reserved. 0896-8608/05 $3.00 +.00 Copyright 2005 International Society for Peritoneal Dialysis ISPD GUIDELINES/RECOMMENDATIONS
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationHow is Ireland performing on antibiotic prescribing?
European Antibiotic Awareness Campaign 2016 November Webinar Series on Antibiotic Prescribing How is Ireland performing on antibiotic prescribing? Dr Rob Cunney National Clinical Lead HCAI AMR Clinical
More informationSurveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at Chiang Mai University Hospital,
Original Article Vol. 28 No. 1 Surveillance of Antimicrobial Resistance:- Chaiwarith R, et al. 3 Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at
More informationDETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams
DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationDR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationRETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR
Original article RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR R.Sujatha 1,Nidhi Pal 2, Deepak S 3 1. Professor & Head, Department
More informationInfectious Complications in PD. An De Vriese Division of Nephrology and Infectious Diseases AZ Sint-Jan Brugge
Infectious Complications in PD An De Vriese Division of Nephrology and Infectious Diseases AZ Sint-Jan Brugge Prevention of Peritonitis Management of Peritonitis EXIT-SITE CARE: STATE OF THE ART Szeto
More informationAn evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",
More informationProphylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi
Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationProtocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CONTROLLED DOCUMENT
CONTROLLED DOCUMENT Protocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Guideline Clinical The purpose
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More information